Status:
RECRUITING
A Study to Evaluate CM336 in Adults with Autoimmune Bullous Disease
Lead Sponsor:
Shandong First Medical University
Conditions:
Autoimmune Bullous Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease
Eligibility Criteria
Inclusion
- 1\. Confirmed diagnosis of autoimmune bullous disease；
- 2\. Age ≥18 years, regardless of gender；
- 3\. Voluntarily signed informed consent form, with understanding of the study's nature, purpose, procedures, and willingness to comply with trial requirements.
Exclusion
- 1\. History of clinically significant diseases that, in the investigator's judgment, may pose safety risks to the subject during participation；
- 2\. Prior treatment with anti-B-cell maturation antigen (BCMA) therapy；
- 3\. History of allergic reactions to humanized monoclonal antibodies or known allergy to any component of CM336；
- 4\. Any other condition deemed by the investigator to render the subject unsuitable for study participation.
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06900010
Start Date
April 1 2025
End Date
January 1 2027
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Hospital Affiliated to Shandong First Medical University
Jinan, China